Výsledky vyhledávání - "Regina, Jitschin"

Akademický článek

Accumulation of T-cell-suppressive PD-L1high extracellular vesicles is associated with GvHD and might impact GvL efficacy

Autor: Regina Jitschin, Simon Völkl, Andreas Mackensen, Dimitrios Mougiakakos, Andreas Gießl, Heiko Bruns, Martin Böttcher, Rebecca Baur, Andrej Stoll, Thomas Fischer, Franziska Karl, Romy Böttcher-Loschinski, Cindy Flamann, Ursula Schlötzer-Schrehardt, Denis M Schewe

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 11, Iss 3 (2023)

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) represents the only curative treatment option for a number of hemato-oncological disorders. In fact, allo-HSCT is considered as one of the most successful immunotherapies as its clinical

Externí odkaz: https://doaj.org/article/03f44df1f3a242ae85281eb8bc2b8891

Zobrazit plný text záznamu

Akademický článek

Thrombopoietin receptor agonists for acquired thrombocytopenia following anti-CD19 CAR-T-cell therapy: a case report

Autor: Regina Jitschin, Simon Völkl, Andreas Mackensen, Dimitrios Mougiakakos, Daniela Schmidt, Maike Büttner-Herold, Rebecca Baur, Soraya Kharboutli, Andrej Stoll, Wolf Rösler

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)

Chimeric antigen receptor (CAR)-modified T-cells targeting CD19 represent a promising therapy for relapsed or refractory (r/r) lymphoma and leukemia. The most common adverse events are immune related and include cytokine release syndrome and neurotox

Externí odkaz: https://doaj.org/article/3a73d5b864f04cb082724c98e4cd6d5d

Zobrazit plný text záznamu

Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib

Autor: Lukas, Häselbarth, Axel, Karow, Kristin, Mentz, Martin, Böttcher, Oisin, Roche-Lancaster, Manuela, Krumbholz, Regina, Jitschin, Dimitrios, Mougiakakos, Markus, Metzler

Publikováno v: Cancer Immunology, Immunotherapy. 72:1661-1672

T cell function is central to immune reconstitution and control of residual chronic myeloid leukemia (CML) cells after treatment initiation and is associated with achieving deep molecular response as a prerequisite for treatment-free remission, the u

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3df2e14101a09e455e48fbac5177b84a
https://doi.org/10.1007/s00262-022-03361-8

Zobrazit plný text záznamu

Akademický článek

CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells

Autor: Regina Jitschin, Domenica Saul, Martina Braun, Sehmus Tohumeken, Simon Völkl, Roman Kischel, Michael Lutteropp, Cedric Dos Santos, Andreas Mackensen, Dimitrios Mougiakakos

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-6 (2018)

Abstract Acute myeloid leukemia (AML) is the most common acute leukemia amongst adults with a 5-year overall survival lower than 30%. Emerging evidence suggest that immune alterations favor leukemogenesis and/or AML relapse thereby negatively impacti

Externí odkaz: https://doaj.org/article/1c9a3d273f454e1ba02104b527ded32d

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání